PMGC HOLDINGS INC (ELAB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.92-1.03%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ELAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -77.0% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of —
ELAB — divestiture
Dated 2026-11-02
Entry into a Material Definitive Agreement. Subscription Agreement for Secured Debentures of Nuclea Energy Canada Inc. On October 30, 2026, PMGC Holdings Inc. (the “Company”) entered into a Subscription Agreement (the “Subscription Agreement”) with Nuclea Energy Canada Inc., a corporation existing under the Business Corporations Act (British Columbia) (“Nuclea Canada”), pursuant to which the Company agreed to subscribe for and purchase US$1,845,000 aggregate principal amount of secured debent…
Why it matters: Naming a lead and backup would show that the four early candidates have narrowed to compounds for more study.
Supportive ifNorthStrive names a lead compound and backup after Phase III, with the planned panel and ATP results reported.
Worry ifNorthStrive reports no lead or backup, or says Phase III results do not support more development.
Why it matters: PMGC has announced a buyback and securities agreements. The next filing can show whether these plans affect cash or share rights.
Watch forA filing shows the buyback is complete, with the number of shares bought and cash amount disclosed.
Also watch forA filing shows the buyback was canceled or delayed, or reports new terms that change security holders' rights.
Why it matters: PMGC's next results can show how its acquired aerospace business is doing. A&B reported higher revenue and profit for the three months ended February 28, 2026.
Watch forThe November 13 report gives A&B revenue and profit figures. Both show year-over-year growth.
Also watch forThe November 13 report shows A&B revenue or profit below the prior-year quarter, or gives no A&B update.
Why it matters: The July results came from early cell tests. Confirmation in mature muscle cells would support the next step for all four compounds.
Supportive ifYuva reports that Expansion Phase II confirms ANT1 induction in mature muscle cells and ranks compounds for the next phase.
Worry ifYuva reports that the compounds lose ANT1 activity in mature muscle cells. Or Phase II gives no ranked go/no-go data.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$272 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $2,039 loss on $10,000 · 20.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,997 loss on $10,000 · 100.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The August term sheet is non-binding. A signed deal would show that the planned aerospace partnership moved beyond talks.
Supportive ifPMGC or Orbit2Orbit announces a signed, binding agreement that lays out the planned joint work.
Worry ifThe parties end talks, or no binding agreement is announced and the term sheet lapses.